跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
HPK1 inhibitors (cancer)
首页
药物
HPK1 inhibitors (cancer)
HPK1 inhibitors (cancer)
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER
申请人: ASTRAZENECA AB
优先权: 2021
CN
EP
US
WO
5 件公开
2,3-DIHYDRO-1H-PYRROLO[3,4-C]PYRIDIN-1-ONE DERIVATIVES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER
申请人: PFIZER
优先权: 2018
CN
EP
WO
3 件公开
Bicyclic HPK1 inhibitors
申请人: JANSSEN PHARMACEUTICA NV
优先权: 2020
US
HPK1 inhibitors
申请人: JANSSEN PHARMACEUTICA NV
优先权: 2020
US
(7-{1H,2H,3H-PYRIDO [2,3-B][1,4]OXAZIN-7-YL}-5H,6H,7H,8H-PYRIDO[3,4-D]PYRIMIDIN-2-YL)AMINE DERIVATIVES AS BIFUNCTIONAL DEGRADERS OF HPK1 FOR THE TREATMENT OF CANCER
申请人: MERCK PATENT GMBH
优先权: 2024
WO
HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF HPK1
申请人: MERCK PATENT GMBH
优先权: 2024
WO
Solid forms of an HPK1 inhibitor
申请人: INCYTE CORP
优先权: 2019
CN
US
3 件公开
Polysubstituted benzene derivative and composition and application thereof
申请人: KANGMAI DISEN BEIJING MEDICINE TECH CO LTD
优先权: 2023
CN
药物
反馈